Figure 2
Median duration of treatment by (A) CpG2 methylation status (< 52% vs. ≥ 52%) and (B) CD95L expression (positive vs. negative).
Figure 2 | Scientific Reports
Median duration of treatment by (A) CpG2 methylation status (< 52% vs. ≥ 52%) and (B) CD95L expression (positive vs. negative).
